ClinicalTrials.gg
RecruitingNCT03559114PROTESTUpdated Sep 19, 2024

PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)

A Phase 3 interventional study of Dalteparin and Saline in Traumatic Brain Injury, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 12 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Sunnybrook Health Sciences Centre · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2018; still recruiting 8 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Brain Injuries, Traumatic with a site in Canada — 20 open to participants now, 22 under way, 2 of them phase 3. Brain Injuries, Traumatic · Canada.

Planned enrollment
2nd of 51
1,100 · median 70
Started
2018
with 6 others
Phase 3
6 of 69
1 open now
Primary completion
2026-12
later than 12 of 21 live
Registered
41st of 69
by date
Lead sponsor
4 of 69
Sunnybrook Health Sciences Centre

Among the 69 studies in Brain Injuries, Traumatic with a site in Canada, this one is the 2nd largest by planned enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2018, is one of 6 in phase 3, reaches primary completion later than 12 of the 21 other live ones, and was the 41st registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

20 of the 69 studies in Brain Injuries, Traumatic with a site in Canada are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Brain Injuries, Traumatic with a site in Canada, or all of them as a file.
02

Study summary

This is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).

Read the detailed description

Patients with severe brain injury are at risk for developing blood clots in their legs, which can travel to the lungs. This potentially serious complication is known as venous thromboembolism (VTE). Anticoagulants are commonly used to prevent VTE in hospital patients. However, in patients with major head injury, anticoagulant prevention is commonly delayed for the fear that it can potentially lead to further bleeding in the brain. Another method that aims to prevent blood clots involves the use of sequential compression device (SCD) that compress the legs and increase the flow of blood in the leg veins.

This study will compare results from patients who receive the SCDs only to those who receive both SCD and anticoagulants. The outcome of this study will provide information about how best to prevent blood clots while not increase brain bleeding after head injury.

03

Conditions studied

  • Traumatic Brain Injury

Keywords

  • Sequential Compression Device
  • Anticoagulant Thromboprophylaxis
  • Deep Vein Thrombosis
  • Sub Cutaneous
  • VTE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The pragmatic nature of this study seeks to include all consecutive patients presenting with significant TBI, regardless of whether ICB is evident at presentation. Inclusion criteria are the following:

i) Patients with severe TBI defined as GCS of ≤8, or

ii) Patients with moderate TBI defined as GCS = 9-12, admitted to ICU, with at least some ICB present on initial CT scan and any of the following:

  1. Requiring invasive mechanical ventilation at the time of screening
  2. Increased ICB on repeat CT scan compared to initial CT scan

iii) Upon randomization the patient will be able to receive the first dose of study drug in the first 3 calendar days from the time of injury

iv) ≥ 18 years of age

Exclusion criteria

Exclusion Criteria

All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study:

i) Known to FRAGMIN (Dalteparin), or its constituents including benzyl alcohol or to other low molecular weight heparins and/or heparins or pork products

ii) Known history of confirmed or suspected immunologically-mediated heparin-induced thrombocytopenia (delayed-onset severe thrombocytopenia), and/or in patients with a known history of a positive in vitro -aggregation test in the presence of FRAGMIN (Dalteparin) is positive

iii) Known septic endocarditis

iv) Uncontrollable active bleeding

v) Known major blood clotting disorders

vi) Known acute gastroduodenal ulcer (with active bleeding)

vii) Severe uncontrolled hypertension (i.e. BP>210 despite medications)

viii) Known diabetic or hemorrhagic retinopathy

ix) Anticipated to be unable to receive SCD on at least one lower extremity due to nature of injuries for duration of intervention period

x) Presence of another confounding factor that can adequately explain the poor GCS at time of presentation (e.g. drug toxicity, seizure)

xi) Known presence of irreversible coagulopathies

xii) Known Pregnancy

xiii) Participants extremely low weight (\<45 kg), or extremely high weight (>120kg)

xiv) Not expected to survive more than 48 hours from admission

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,100 participants (estimated)

Study arms

  • Active comparator
    Anticoagulant

    Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.

    Drug: Dalteparin

  • Placebo comparator
    Saline

    Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.

    Drug: Saline

Interventions

  • Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.

    Also known as: Fragmin

  • DrugSaline

    Saline in prophylactic doses administered daily if screening criteria are satisfied.

    Also known as: Sodium Chloride

06

What researchers measure

Primary outcomes

  1. Clinically important VTE

    Composite outcome of clinically-important VTE within 7±1 days after randomization defined as any of: 1. Symptomatic, objectively-confirmed pulmonary embolism (PE), or 2. Symptomatic, objectively-confirmed, proximal leg deep vein thrombosis (DVT), or 3. Proximal (above knee) leg DVT on compression ultrasonography on Day 7±1

    Time frame: 8 days

Secondary outcomes

  1. Clinically-important ICB (Intracranial bleeding) progression

    Clinically-important ICB progression within 7±1 days after randomization , as defined by having (1) any increase in volume of blood in the brain on any CT scan within 7±1 days relative to initial CT scan on Day 0\* AND (2) clinical worsening within 24 hours of this CT scan, defined by one or more of the following: * Surgical intervention related to increased ICB after Day 0 (craniotomy/craniectomy, ICP monitor, external ventricular drain) * Decrease of GCS (Glasgow Coma Scale) by at least 2 points not related to sedation * Increase in ICP \>5 mmHg on 2 occasions at least 6 hours apart despite medical therapy (if ICP monitor is in place) * Death

    Time frame: 7 days

  2. Objectively confirmed new or progressing ICB on radiology,

    Assessed by comparing the initial brain CT (Day 0) to that performed within 8±1 days following randomization (or most recent prior to death).

    Time frame: 8 days

  3. 180-day Mortality

    Mortality at 180 days

    Time frame: 180 days

  4. 7-day Mortality

    Mortality at 7 days

    Time frame: 7 days

  5. 30-day Mortality

    Mortality at 30 days

    Time frame: 30 days

  6. Delayed VTE after day 7

    Any clinically important VTE occurring between Day 8 to Day 30 detected by treating clinicians

    Time frame: 30 days

  7. Functional neurological outcome at day 30 as measured by Glasgow Outcome Scale Extended

    Glasgow Outcome Scale Extended (GOSE) at Day 30±5 by phone interview.

    Time frame: 30 days

  8. Functional neurological outcome at day 180 as measured by Glasgow Outcome Scale Extended

    Glasgow Outcome Scale Extended (GOSE) at Day 180±14 by phone interview.

    Time frame: 180 days

  9. Quality of life outcome at 30 days as measured by the EuroQol5D

    EQ-5D (EuroQol 5D) at Day 30±5 by phone interview.

    Time frame: 30 days

  10. Quality of life outcome at 180 days as measured by the EuroQol5D

    EQ-5D (EuroQol 5D) at Day 180±14 by phone interview.

    Time frame: 180 days

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Dec 2026, 101 months after the start.

Of 30 phase 3 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 69. This study's planned 101 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2018
First posted
Jun 15, 2018
StartActual
Jul 19, 2018
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03559114
Collaborators
Sunnybrook Research Institute
Responsible party
Sponsor
First posted
Jun 15, 2018
Start date
Jul 19, 2018
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 19, 2024

Study contacts

Farhad Pirouzmand, MD, MSc, FRCSC
Contact
farhad.pirouzmand@sunnybrook.ca
416-480-6100 ext. 5263
Kanthi Kavikondala, CCRP
Contact
protest@sunnybrook.ca
416-480-6100 ext. 87546
Farhad Pirouzmand, MD, MSc, FRCSC
principal investigator · Sunnybrook Health Sciences Centre
Damon Scales, MD, PhD, FRCPC
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalteparin

Start the discussion